Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Rückle
Observed names:
Ruckle, T.,
Rückle, Thomas,
T Ruckle,
T. Ruckle,
T. Rückle,
Thomas Ruckle,
Thomas Rückle
show all 7
Institution:
BioMed X
Observed institutions:
Babraham Institute,
Ludwig Cancer Research,
Merck Serono S.A. (Switzerland),
BioMed X,
University College London,
École Polytechnique Fédérale de Lausanne,
Medicines for Malaria Venture,
University of Tübingen,
University of Lausanne
show all 9
OpenAlex ID:
A5004799865
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
2005
·
Montserrat Camps
, Thomas Rückle
, et al.
·
Nature Medicine
·
823
PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus
2005
·
Domingo F Barber
, Almira Bartolomé
, et al.
·
Nature Medicine
·
341
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
2010
·
Alex Berndt
, Simon Miller
, et al.
·
Nature Chemical Biology
·
320
Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
2008
·
Elisa Ciraolo
, Manuela Iezzi
, et al.
·
Science Signaling
·
299
PI3Kγ inhibition: towards an 'aspirin of the 21st century'?
2006
·
Thomas Rückle
, Matthias K. Schwarz
, et al.
·
Nature Reviews Drug Discovery
·
260
Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ
2006
·
Vincent Pomel
, Jasna Klicic
, et al.
·
Journal of Medicinal Chemistry
·
231
Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells
2005
·
Antonio Bilancio
, Klaus Okkenhaug
, et al.
·
Blood
·
226
Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease
2003
·
Céline Adessi
, Marie-José Frossard
, et al.
·
Journal of Biological Chemistry
·
220
PDF
BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity
2008
·
Cristina Gamell
, Nelson Osses
, et al.
·
Journal of Cell Science
·
160
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
2018
·
Alejandro Llanos-Cuentas
, Martin Casapia
, et al.
·
The Lancet Infectious Diseases
·
154
PDF
Regulation of the severity of neuroinflammation and demyelination by TLR‐ASK1‐p38 pathway
2010
·
Xiaoli Guo
, Chikako Harada
, et al.
·
EMBO Molecular Medicine
·
151
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
2017
·
James S McCarthy
, Julie Lotharius
, et al.
·
The Lancet Infectious Diseases
·
140
PDF
Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-γ Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes
2008
·
Anne Fougerat
, Stéphanie Gayral
, et al.
·
Circulation
·
139
Inactivation of PI3Kγ and PI3Kδ distorts T-cell development and causes multiple organ inflammation
2007
·
Hong Ji
, Felix Rintelen
, et al.
·
Blood
·
127
PDF
Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110δ but Not p110γ Promotes Optimal Allergic Responses In Vivo
2008
·
Khaled Ali
, Montserrat Camps
, et al.
·
The Journal of Immunology
·
125
PDF
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study
2016
·
James S. McCarthy
, Thomas Rückle
, et al.
·
Malaria Journal
·
124
PDF
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
2017
·
Mihály Sulyok
, Thomas Rückle
, et al.
·
The Lancet Infectious Diseases
·
115
PDF
Chemokine inhibition – why, when, where, which and how?
2004
·
Z. Johnson
, C.A. Power
, et al.
·
Biochemical Society Transactions
·
113
The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion
2007
·
Nayoung Kim
, Aurore Saudemont
, et al.
·
Blood
·
107
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
2021
·
Hans-Peter Hartung
, Tobias Derfuss
, et al.
·
Multiple Sclerosis Journal
·
97
PI3Kγ regulates cartilage damage in chronic inflammatory arthritis
2009
·
Silvia Hayer
, Noreen Pundt
, et al.
·
The FASEB Journal
·
81
Importance of Phosphoinositide 3-Kinase γ in the Host Defense against Pneumococcal Infection
2007
·
Ulrich A. Maus
, Myriam Backi
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
77
Phosphoinositide-3 Kinase γ Activity Contributes to Sepsis and Organ Damage by Altering Neutrophil Recruitment
2010
·
Erica L. Martin
, Danielle G. Souza
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
74
A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
2019
·
James S. McCarthy
, Thomas Rückle
, et al.
·
Antimicrobial Agents and Chemotherapy
·
72
PDF
Phosphoinositide 3-Kinase γ Inhibition Plays a Crucial Role in Early Steps of Inflammation by Blocking Neutrophil Recruitment
2007
·
Chiara Ferrandi
, Vittoria Ardissone
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
70
Show more works
View as search
Works count:
79
Citation count:
5,378
H-index:
36
I10-index:
42
Year
Topic
Type